Screener
Vir Biotechnology, Inc. VIR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
FAQ
- What is Vir Biotechnology, Inc.'s cash & equivalents?
- Vir Biotechnology, Inc. (VIR) reported cash & equivalents of $287.6M in Q2 2026.
- How has Vir Biotechnology, Inc.'s cash & equivalents changed year-over-year?
- Vir Biotechnology, Inc.'s cash & equivalents decreased by 6.1% year-over-year, from $306.28M to $287.6M.
- What is the long-term trend for Vir Biotechnology, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Vir Biotechnology, Inc.'s cash & equivalents has grown at a -11.2% compound annual growth rate (CAGR), from $436.58M to $241.07M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Vir Biotechnology, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude